A randomised, double-blind, placebo-controlled, cross-over, single rising-dose study of CER-001 in healthy male and female volunteers

Trial Profile

A randomised, double-blind, placebo-controlled, cross-over, single rising-dose study of CER-001 in healthy male and female volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs CER 001 (Primary)
  • Indications Dyslipidaemias; Lipid metabolism disorders
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Cerenis Therapeutics
  • Most Recent Events

    • 17 Feb 2017 Results published in the Clinical Drug Investigation
    • 16 Nov 2011 Results presented at the 84th Annual Scientific Sessions of the American Heart Association.
    • 19 May 2010 Trial reported as 'completed' according to a Cerenis Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top